A 16-year-old boy died after receiving gene therapy for a rare muscular dystrophy
Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06. The security is pacing for its worst single-day percentage loss since October 2023 after the gene-editing company revealed a 16-year-old boy died from acute liver failure after receiving its gene therapy for a rare muscular dystrophy. Year to date, the equity is down 37.5%.
Beam Therapeutics Inc (NASDAQ:BEAM) is down 6.8% to trade at $22.85 at last glance, brushing off a price-target hike from Leerink Partners to $42 from $37. The shares are track for their third loss in four sessions, and earlier today slipped to their lowest level since January, as they test the supportive $22 level. The 20-day moving average has acted as resistance so far this month, and in the last 12 months the stock shed over 32%.
Crispr Therapeutics AG (NASDAQ:CRSP) was last seen down 4.6% to trade at $40.87. A floor at $40 looks ready to contain today's losses, after stopping a pullback form the equity's highest level since November. Though overhead pressure at the 100-day moving average remains and shares carry a 42.6% year-over-year deficit, so far in 2025 they have added 4%.